Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts
It is becoming clear that combination strategies will be necessary to augment cancer immunotherapy. We report that combination anti-OX40/anti-CTLA-4 mAb immunotherapy improves survival by enhancing effector T cell expansion and function, even while inducing Th2 cytokine production. Furthermore, IL-4...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Landes Bioscience
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091104/ |